The University of California-San Francisco has a long history of involvement in cooperative group efforts in general and in Cancer and Leukemia Group B in particular. This application describes, in detail, the scope and breadth of cancer research at the UCSF Helen Diller Family Comprehensive Cancer Center as well as the participation in and leadership positions held by UCSF investigators within CALGB. This application is divided into three sections: I. Major Research Interests/Capabilities of the University of California - San Francisco Cancer Center, II. Organization employed for institutional Group participation and III. Scientific and Clinical Contributions to the Group and Plans for the award period. This is a new U10 application for UCSF. I. The University of California-San Francisco Helen Diller Family Comprehensive Cancer Center (UCSFHDFCCC) is an NCI-designated matrix center involving a wide range of interdisciplinary research personnel in the laboratory, clinical, and population sciences. In total, the UCSF-HDFCCC integrates the activities of 331 members (247 program members, 23 members, 42 associate members, and 19 affiliate members) working at four major campus and hospital locations. II. Robust participation in CALGB related activities is a high priority in the UCSF-HDFCCC. As such, a permanent CALGB infrastructure has been created that consists of a principal investigator, internal advisory board, a program manager, regulatory analyst, investigational pharmacist and clinical research coordinators. III. UCSF CALGB members have served or are serving as chairs or co-chairs of 7 currently active protocols and have served as chairs of 6 other protocols during the past 8 years. Further, 8 protocols proposed by UCSF investigators have been approved by the Executive Committee and will be open to accrual within a 12-month time frame. In addition to this scientific leadership, two CALGB committees (GU and Transplant) are chaired by UCSF faculty. These are detailed in this application.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA138561-02
Application #
7812161
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
2009-04-24
Project End
2012-03-31
Budget Start
2010-04-01
Budget End
2011-03-31
Support Year
2
Fiscal Year
2010
Total Cost
$112,515
Indirect Cost
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
McCleary, Nadine J; Hubbard, Joleen; Mahoney, Michelle R et al. (2018) Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance). J Geriatr Oncol 9:24-31
Fadelu, Temidayo; Zhang, Sui; Niedzwiecki, Donna et al. (2018) Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance). J Clin Oncol 36:1112-1120
Van Blarigan, Erin L; Fuchs, Charles S; Niedzwiecki, Donna et al. (2018) Marine ?-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev 27:438-445
Innocenti, Federico; Jiang, Chen; Sibley, Alexander B et al. (2018) Genetic variation determines VEGF-A plasma levels in cancer patients. Sci Rep 8:16332
Van Blarigan, Erin L; Ou, Fang-Shu; Niedzwiecki, Donna et al. (2018) Dietary Fat Intake after Colon Cancer Diagnosis in Relation to Cancer Recurrence and Survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev 27:1227-1230
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744
Parsons, J Kellogg; Pierce, John P; Mohler, James et al. (2018) Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer. BJU Int 121:534-539
Holstein, Sarah A; Jung, Sin-Ho; Richardson, Paul G et al. (2017) Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol 4:e431-e442
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050
Fuchs, Charles S; Niedzwiecki, Donna; Mamon, Harvey J et al. (2017) Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). J Clin Oncol 35:3671-3677

Showing the most recent 10 out of 14 publications